OS by age and sMut status of the entire cohort and favorable risk subset. (A) Median OS was shorter in older patients (age ≥60) with NPM1-mutated AML with sMut than those without sMut. (12.6 months vs 26.1 months; P < .01). (B) When restricted to only patients with favorable risk, median OS was again significantly shorter in the older, sMut subset.